0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessResponses and prolonged PFS were observed in many tumours with BRAF mutations, including HCL, ECD, ovarian carcinoma, gliomas, ganglioglioma, and sarcomas. Although not all cancer types responded, vemurafenib is an agnostic oncogene therapy of cancers.
Jean Yves Blay, Claire Cropet, Sandrine Mansard, Yohann Loriot, Christelle de la Fouchardière, Julien Haroche, Delphine Topart, David Tougeron, Benoît You, Antoîne Italiano, Valérie Le Brun-Ly, Jean-Marc Ferrero, Nicolas Penel, Michel Fabbro, Xavier Troussard, David Malka, Isabelle Ray‐Coquard, Sophie Leboulleux, Aude Fléchon, E. Maubec, J. Charles, Stéphane Dalle, S. Taïeb, Gabriel Garcia, A.M. Mandache, N. Colignon, Marie Gavrel, F. Nowak, N. Hoog Labouret, Céline Mahier - Aït Oukhatar, Carlos Gomez‐Roca (2023). Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma. , 8(6), DOI: https://doi.org/10.1016/j.esmoop.2023.102038.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2023
Authors
31
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1016/j.esmoop.2023.102038
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
